SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Energy Transfer LP engages in natural gas pipeline transportation and transmission services. It operates through the following segments: Intrastate Transportation and Storage, Interstate Transportation and Storage, Midstream, NGL and Refined Products Transportation and Services, Crude Oil Transportation and Services, Investment in Sunoco LP, Investment in USAC, and All Other. The Intrastate Transportation and Storage segment owns and operates natural gas transportation pipelines. The Interstate Transportation and Storage segment includes transportation pipelines, storage facilities, and gathering systems and delivery of natural gas to industrial end-users and other pipelines. The Midstream segment consists of natural gas gathering, compression, treating, processing, storage, and transportation. The NGL and Refined Products Transportation segment engages in the operations transport, store and execute acquisition, and marketing activities utilizing a complementary network of pipelines, storage and blending facilities, and strategic off-take locations that provide access to multiple NGL markets. The Crude Oil Transportation and Services segment provides transportation, terminalling, acquisition, and marketing services to crude oil markets. The Investment in Sunoco LP segment refers to the distribution of motor fuels to independent dealers, distributors, and other commercial customers and the distribution of motor fuels to end-user customers at retail sites. The Investment in USAC segment offers compression services to its customers in connection with infrastructure applications including both allowing for the processing and transportation of natural gas through the domestic pipeline system and enhancing crude oil production through artificial lift processes. The company was founded by Kelcy L. Warren in 1996 and is headquartered in Dallas, TX.

Energy Transfer LP - Unit

Energy Transfer LP Unit

ETs recent weakness is being debated after a reported quarterly earnings miss, despite higher full-year EBITDA guidance; traders also point to interest-rate concerns, election uncertainty, and questions about whether NGL profits will repeat. Some investors view the pullback as a buying opportunity, citing the distribution and potential data-center gas demand, though several prospective contracts remain unconfirmed.

ProShares Trust II - ProShares UltraShort Bloomberg Crude Oil -2x Shares

ProShares UltraShort Bloomberg Crude Oil

SCO is drawing attention as traders use the leveraged inverse crude ETF to bet on oils direction amid shifting Iran and Strait of Hormuz conflict and peace-deal expectations. Some expect de-escalation and lower oil prices to lift SCO, while others complain that futures exposure, backwardation and daily-reset decay have caused it to lag crudes moves.

Victoria's Secret & Co. operates as a lingerie, clothing and beauty retailer. It offers bras, panties, lingerie, sleepwear, apparel, sport and swim apparel, and beauty products. The company was founded in 1963 and is headquartered in Reynoldsburg, OH.

Victoria`s Secret & Co

Victorias Secrets turnaround momentum and strong earnings-driven rally, alongside analyst upgrades, are fueling bullish interest and technical-breakout chatter. Traders remain divided, with some citing improving brand demand and guidance while skeptics warn the run-up may be overextended and vulnerable to a pullback.

Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in San Diego, CA.

Kura Oncology Inc

Competitive J&J bleximenib data has raised concern about future share for Kuras menin inhibitor, with traders debating whether differences in prior venetoclax exposure make the comparison misleading. Some view the selloff as an overreaction and are looking to ASH data for clearer evidence on ziftomenibs frontline potential.

Chevron Corp. engages in the provision of oil and gas energy solutions. It provides crude oil and natural gas, manufactures transportation fuels, lubricants, petrochemicals, and additives, and develops technologies that enhance business and the industry. It operates through the Upstream and Downstream segments. The Upstream segment consists of the exploration, development, and production of crude oil and natural gas, the liquefaction, transportation, and regasification associated with liquefied natural gas, the transporting of crude oil by major international oil export pipelines, the processing, transporting, storage, and marketing of natural gas, and a gas-to-liquids plant. The Downstream segment consists of the refining of crude oil into petroleum products, the marketing of crude oil and refined products, the transporting of crude oil and refined products by pipeline, marine vessel, motor equipment, and rail car, and the manufacturing and marketing of commodity petrochemicals and plastics for industrial uses and fuel & lubricant additives. The company was founded on September 10, 1879 and is headquartered in Houston, TX.

Chevron Corp.

Chevrons quarterly earnings beat, with unusually strong refining profits amid tight diesel supply and record U.S. refinery throughput, is driving attention. Traders are weighing the stronger cash flow and debt reduction against concerns that refining gains may be temporary, while some are also debating whether the recent rally has run too far.

Berkshire Hathaway, Inc. is a holding company, which engages in the provision of property and casualty insurance and reinsurance, utilities and energy, freight rail transportation, finance, manufacturing, and retailing services. It operates through the following segments: Insurance, Burlington Northern Santa Fe, LLC (BNSF), Berkshire Hathaway Energy (BHE), Pilot Travel Centers (PTC), Manufacturing, McLane, and Service and Retailing. The Insurance segment includes the underwriting of GEICO, Berkshire Hathaway Primary Group, and Berkshire Hathaway Reinsurance Group. The BNSF segment involves the operation of railroad systems. The BHE segment focuses on regulated electric and gas utility, power generation and distribution, and real estate brokerage activities. The PTC segment consists of managing travel centers and marketing of wholesale fuel. The Manufacturing segment refers to industrial, consumer and building products, home building, and related financial services. The McLane segment covers the wholesale distribution of groceries and non-food items. The Service and Retailing segment relates to the provision of shared aircraft ownership programs, aviation pilot training, electronic components distribution, retailing businesses, automobile dealerships and trailer, and furniture leasing services. The company was founded by Oliver Chace in 1839 and is headquartered in Omaha, NE.

Berkshire Hathaway Inc. - Ordinary Shares - Class B

Berkshires Q3 results are drawing attention, with weaker operating performanceparticularly in insuranceset against a sharp increase in share repurchases. Traders are split between concern over the earnings softness and approval of the buybacks as a sign of management confidence and disciplined capital allocation.

Zebec Network (ZBCN) is a cryptocurrency launched in 2022and operates on the Solana platform. Zebec Network has a current supply of 99,998,768,505.961324. The last known price of Zebec Network is 0.00185282 USD and is down -2.31 over the last 24 hours. It is currently trading on 133 active market(s) with $11,016,611.66 traded over the last 24 hours. More information can be found at https://zebec.io/.

Zebec Network

Zebecs payroll and payments partnershipsespecially the MoneyGram/Stellar integration and reported Germany/AllUnity deploymentare fueling discussion, alongside unconfirmed speculation about Robinhood. Bulls see these developments as signs of growing adoption, while skeptics argue that partnerships have yet to translate into sustained ZBCN demand or stronger price performance.

American Express Co. engages in the provision of card-issuing, merchant-acquiring, and card network businesses. Its products and services include credit cards, business credit cards, corporate programs, gift cards, savings accounts and CDs, and the American Express App. It operates through the following segments: the United States Consumer Services (USCS), Commercial Services (CS), International Card Services (ICS), Global Merchant and Network Services (GMNS), and Corporate and Other. The USCS segment includes proprietary consumer cards and provides services to United States consumers. The CS segment offers corporate and small business cards and provides services to United States businesses. The ICS segment provides consumers, small businesses, and corporate cards outside the United States. The GMNS segment is involved in operating a global payments network that processes and settles card transactions, acquires merchants, and provides multi-channel marketing programs and capabilities, services and data analytics. The Corporate and Other segment covers corporate functions and certain other businesses and operations. It also operates through the following geographical segments: United States, EMEA, APAC, LACC, and Other. The EMEA segment represents Europe, the Middle East, and Africa. The APAC segment refers to Asia Pacific, Australia, and New Zealand. The LACC segment focuses on Latin America, Canada, and the Caribbean. The Other segment includes net costs which are not directly allocated to specific geographic regions. The company was founded by Henry Wells, William G. Fargo, and John Warren Butterfield on March 28, 1850 and is headquartered in New York, NY.

American Express Co.

American Expresss earnings beat and higher full-year outlook failed to lift the shares, with traders focused instead on its planned workforce cuts tied to restructuring and AI investment, alongside a slight revenue miss. The reaction is divided: bears cite possible consumer softness and concern about the cuts, while bulls view the selloff as an overreaction to otherwise resilient spending and results.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

LUNRs sharp rebound after a steep selloff has traders debating whether short covering and a broader space-sector bounce are driving the move. Some speculate that NASAs upcoming CLPS 2.0 awards or other contract news could provide a catalyst, while others view the rally as temporary; no specific new award is confirmed in the discussion.

Pepe (PEPE) is a cryptocurrency launched in 2023and operates on the Ethereum platform. Pepe has a current supply of 413,772,350,098,130.40630647. The last known price of Pepe is 0.00000498 USD and is up 2.29 over the last 24 hours. It is currently trading on 729 active market(s) with $440,504,313.03 traded over the last 24 hours. More information can be found at https://www.pepe.vip/.

Pepe

PEPE is drawing attention for volatile swings around the 0.000005 level, with traders watching whether it can break and hold above resistance after repeated pullbacks. Dip buyers expect a renewed meme-coin rally, while skeptics view the bounces as temporary and point to weak price action and broader crypto-market pressure.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC...

Citigroup Lowers Oric Pharmaceuticals (NASDAQ:ORIC) Price Target to $16.00

Citigroup lowered their price objective on shares of Oric Pharmaceuticals from $17.00 to $16.00 and set a 'buy' rating on the stock in a research report on Tuesday...

Oric Pharmaceuticals (NASDAQ:ORIC) Announces Quarterly Earnings Results, Misses Estimates By $0.03 EPS

Oric Pharmaceuticals (NASDAQ:ORIC - Get Free Report) issued its quarterly earnings results on Monday. The company reported ($0.34) earnings per share for the quarter, missing analysts' consensus estimates of ($0.31) by ($0.03...

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Given Consensus Rating of "Moderate Buy" by Brokerages

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the fourteen ratings firms that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, two have assigned...

Oric Pharmaceuticals (ORIC) to Release Earnings on Monday

Oric Pharmaceuticals (NASDAQ:ORIC) will be releasing its Q1 2026 earnings before the market opens on Monday, May 4. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-4-oric-pharmaceuticals-inc-stock...

ORIC Investors Have Opportunity to Join ORIC Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors ofORIC Pharmaceuticals, Inc. (Oricor the Company) (NASDAQ:ORIC) for violations of the securities laws.The investigation focuses on whether the Company issued false...

Oric Pharmaceuticals (NASDAQ:ORIC) Stock Price Up 6.5% - Still a Buy?

Oric Pharmaceuticals (NASDAQ:ORIC) Trading Up 6.5% - Here's Why...

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives Consensus Rating of "Moderate Buy" from Brokerages

Shares of Oric Pharmaceuticals, Inc. (NASDAQ:ORIC - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the fourteen brokerages that are currently covering the company...

Oric Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of cancer treatments that address mechanisms of therapeutic resistance. It specializes in hormone-dependent cancers, key tumor dependencies, and precision oncology. The company was founded by Charles L. Sawyers, Richard A. Heyman, and Scott Lowe in 2014 and is headquartered in South San Francisco, CA.

ORIC Pharmaceuticals Inc

ORIC Stock Sees Biggest Intraday Slump In Over Four Years – Analyst Says Selloff 'Appears Exaggerated’

Equity

Bullish Sentiment

<ul class="summary-bullets"><li>Jones Research maintained a ‘Buy’ rating on the stock with a $25 price target, according to The Fly.</li><li>Wedbush Securities lowered its price target to $17 from $20 but maintained an ‘Outperform’ rating.</li><li>Cantor Fitzgerald said Rinzimetostat’s efficacy appears comparable to competitor Mevrometostat from Pfizer</li></ul>Shares of Oric Pharmaceuticals (ORIC) plunged 28% on Wednesday as investors reacted to tolerability concerns tied to a higher dose of its prostate cancer drug, even as analysts said the sharp sell-off appears exaggerated.<a href="https://stocktwits.com/symbol/ORIC">ORIC shares</a> recorded their biggest intraday slump in more than four years.<h2 class="st-heading-2">Oric Selects 400 MG Dose Of Rinzimetostat</h2>On Tuesday, Oric <a href="https://stocktwits.com/news-articles/markets/equity/oric-falls-after-hours-on-safety-concerns-around-prostate-cancer-candidate/cZ7HT8GRIVz">announced</a> it selected a lower 400 mg dose of its investigational drug Rinzimetostat. In the Phase 1 trial involving patients with metastatic castration-resistant prostate cancer, the 600 mg dose showed a higher rate of side effects, dose interruptions, and discontinuations when combined with darolutamide.By contrast, the 400 mg dose demonstrated a more manageable safety profile, with mostly mild side effects and only limited severe (Grade 3) events. The company now plans to move forward with the lower dose in a global Phase 3 trial in the first half of 2026.<h2 class="st-heading-2">Analysts Say Selloff is Exaggerated</h2>Despite the sharp selloff, analysts suggest the reaction may be overdone. Jones Research noted that the data appears broadly in line with Pfizer’s competing drug Mevrometostat, while potentially offering a better safety profile, according to The Fly.The firm said the selloff ‘appears exaggerated,” pointing out that Oric’s data is still early, with only about five months of follow-up compared to nine to 10 months for Pfizer’s results. Jones &nbsp;Research maintained a ‘Buy’ rating on the stock with a $25 price target.Other firms, including Cantor Fitzgerald and Wedbush, highlighted that efficacy remains comparable. “Efficacy appears comparable to competitor Mevrometostat from Pfizer, with Rinzi showing a potentially better safety profile,” Cantor said. It has an ‘Overweight’ rating on Oric shares.<h2 class="st-heading-2">Wedbush Says Results broadly In Line With Pfizer’s Drug</h2>Meanwhile, David Nierengarten of Wedbush Securities lowered his price target to $17 from $20 while maintaining an ‘Outperform’ rating. The analyst said Oric’s Phase 1 prostate cancer results are broadly in line with Pfizer’s, even though Oric tested its drug in a sicker patient group.He added that while greater efficacy differences are ideal, better tolerability is important, especially for older patients on long-term treatment, and could influence doctors’ choices if both drugs are similarly effective.Despite the sharp selloff, retail sentiment turned ‘extremely bullish’ from ‘neutral’ a day earlier.One user said the stock has "really good upside potential"<stembedurl>https://stocktwits.com/LF5/message/649195078</stembedurl>The stock has gained more than 10% so far in 2026.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/oric-falls-after-hours-on-safety-concerns-around-prostate-cancer-candidate/cZ7HT8GRIVz">ORIC Falls After Hours On Safety Concerns Around Prostate Cancer Candidate At Higher Doses</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Oric Pharmaceuticals logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Oric shares tanked after the firm selected a lower 400 mg dose of its investigational drug for prostate cancer after its 600 mg dose showed a higher rate of side effects.

ORIC Stock Sees Biggest Intraday Slump In Over Four Years – Analyst Says ‘Selloff Appears Exaggerated’

Pfizer Inc

Up more than 1% 

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Feed

News

Sentiment

Earnings

Fundamentals

Info

ORIC ORIC Pharmaceuticals Inc

Fundamentals

Latest ORIC News